Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

This was the stock's second consecutive day of losses.

Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, after the company posted better-than-expected fourth-quarter ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors.

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...

Shares of Regeneron Pharmaceuticals Inc. slid 3.61% to $665.46 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.03% to 6,068.